-+ 0.00%
-+ 0.00%
-+ 0.00%
Roche's CD20/CD3 bispecific antibody Lunsumio successfully reached the primary endpoint in the critical phase III CELESTIMO study for follicular lymphoma.
Share
Listen to the news
Roche's CD20/CD3 bispecific antibody Lunsumio successfully reached the primary endpoint in the critical phase III CELESTIMO study for follicular lymphoma.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending